Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_assertion type Assertion NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_head.
- NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_assertion description "[Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_provenance.
- NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_assertion evidence source_evidence_literature NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_provenance.
- NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_assertion SIO_000772 19074097 NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_provenance.
- NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_assertion wasDerivedFrom befree-20140225 NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_provenance.
- NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_assertion wasGeneratedBy ECO_0000203 NP336218.RAQFn62-evjsZPqFpJ_CAzNQwqHbe0hhRvn10c2soZmD4130_provenance.